Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADXN NASDAQ:BMRA NYSE:CANF NASDAQ:EVOK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXNAddex Therapeutics$8.06-7.7%$8.46$6.51▼$13.27$8.37M1.63865 shs485 shsBMRABiomerica$3.13-0.9%$3.27$2.08▼$10.16$7.97M0.262.07 million shs76,253 shsCANFCan-Fite BioPharma$0.63-4.8%$0.85$0.63▼$3.12$2.24M1.02208,153 shs146,374 shsEVOKEvoke Pharma$5.45+3.0%$4.57$1.94▼$12.32$8.49M-0.04494,794 shs44,930 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXNAddex Therapeutics0.00%+0.37%-1.72%+4.00%-24.08%BMRABiomerica0.00%-9.80%-3.40%+2.62%-14.95%CANFCan-Fite BioPharma0.00%-4.48%-5.75%-41.27%-72.50%EVOKEvoke Pharma0.00%-1.45%+50.14%+62.40%+23.98%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADXNAddex Therapeutics2.6621 of 5 stars3.53.00.00.03.30.80.6BMRABiomerica0.909 of 5 stars0.05.00.00.02.80.80.0CANFCan-Fite BioPharma1.5133 of 5 stars3.52.00.00.00.00.01.3EVOKEvoke Pharma0.6356 of 5 stars0.05.00.00.02.60.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADXNAddex Therapeutics 3.00Buy$30.00272.44% UpsideBMRABiomerica 0.00N/AN/AN/ACANFCan-Fite BioPharma 3.00Buy$14.002,117.29% UpsideEVOKEvoke Pharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CANF, ADXN, BMRA, and EVOK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/29/2025CANFCan-Fite BioPharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00(Data available from 8/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADXNAddex Therapeutics$460K18.56N/AN/A$10.37 per share0.78BMRABiomerica$5.41M1.48N/AN/A$3.13 per share1.00CANFCan-Fite BioPharma$674K3.32N/AN/A$1.76 per share0.36EVOKEvoke Pharma$10.25M0.83N/AN/A$2.81 per share1.94Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADXNAddex Therapeutics$8.02M-$0.34N/A∞N/A3,584.49%-54.27%-49.15%9/1/2025 (Estimated)BMRABiomerica-$5.98M-$2.32N/A∞N/A-85.42%-85.90%-61.06%N/ACANFCan-Fite BioPharma-$7.63M-$1.79N/AN/AN/AN/AN/AN/AN/AEVOKEvoke Pharma-$5.35M-$2.56N/A∞N/A-42.07%-99.48%-33.58%11/5/2025 (Estimated)Latest CANF, ADXN, BMRA, and EVOK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025EVOKEvoke Pharma-$0.30-$0.62-$0.32-$0.62$3.80 million$3.75 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADXNAddex TherapeuticsN/AN/AN/AN/AN/ABMRABiomericaN/AN/AN/AN/AN/ACANFCan-Fite BioPharmaN/AN/AN/AN/AN/AEVOKEvoke PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADXNAddex TherapeuticsN/A3.023.02BMRABiomericaN/A3.762.76CANFCan-Fite BioPharmaN/A2.93N/AEVOKEvoke PharmaN/A1.371.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADXNAddex Therapeutics16.14%BMRABiomerica22.28%CANFCan-Fite BioPharma21.00%EVOKEvoke PharmaN/AInsider OwnershipCompanyInsider OwnershipADXNAddex Therapeutics15.00%BMRABiomerica15.00%CANFCan-Fite BioPharma0.80%EVOKEvoke Pharma2.29%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADXNAddex Therapeutics301.06 million901,000Not OptionableBMRABiomerica602.55 million2.16 millionOptionableCANFCan-Fite BioPharma83.54 millionN/ANot OptionableEVOKEvoke Pharma41.56 million1.52 millionNot OptionableCANF, ADXN, BMRA, and EVOK HeadlinesRecent News About These CompaniesEvoke Pharma (NASDAQ:EVOK) Stock Rating Upgraded by Wall Street ZenAugust 30 at 2:47 AM | americanbankingnews.comEvoke Pharma, EVERSANA expand GIMOTI access with Omnicell relationshipAugust 26, 2025 | msn.comEvoke Pharma and EVERSANA Expand GIMOTI® Access to Gastro Health and Other Large GI Practices through Omnicell RelationshipAugust 26, 2025 | globenewswire.comEvoke Pharma Announces Listing of New GIMOTI® Patent in FDA Orange BookAugust 21, 2025 | globenewswire.comEvoke Pharma, Inc. (NASDAQ:EVOK) Just Reported Earnings, And Analysts Cut Their Target PriceAugust 17, 2025 | finance.yahoo.comEvoke Pharma Reports Strong Q2 2025 Sales GrowthAugust 15, 2025 | msn.comEvoke Pharma reports Q2 EPS (62c) vs (93c) last yearAugust 14, 2025 | msn.comEvoke Pharma sees FY25 net product sales of approx $16MAugust 14, 2025 | msn.comEvoke Pharma, Inc.: Evoke Pharma Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 14, 2025 | finanznachrichten.deEvoke Pharma Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 14, 2025 | finance.yahoo.comEvoke Pharma Announces Issuance of New U.S. Patent for GIMOTI With Extended Exclusivity to Late 2038August 6, 2025 | globenewswire.comEvoke Pharma Initiates Commercial Manufacturing of Gimoti™August 5, 2025 | cnn.comEvoke Pharma Receives Notice of Allowance for U.S. Patent ... - NasdaqJuly 11, 2025 | nasdaq.comEvoke Pharma, Inc. Receives Patent Allowance for GIMOTI® in ... - NasdaqJuly 11, 2025 | nasdaq.comEvoke Pharma Stock Skyrockets On Patent For Nasal Spray That Eases Stomach Delays; Retail Bulls Pile InJuly 10, 2025 | msn.comEvoke Pharma Receives Notice of Allowance for U.S. Patent Application for GIMOTI Extending Orange Book listings to 2036July 9, 2025 | globenewswire.comBreakeven On The Horizon For Evoke Pharma, Inc. (NASDAQ:EVOK)June 14, 2025 | finance.yahoo.comEvoke Pharma Inc.June 8, 2025 | wsj.comEvoke Pharma Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 13, 2025 | globenewswire.comInizio Evoke appoints Tristen George and Kevin Kaniuga as executive creative directorsMay 10, 2025 | pmlive.comPNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCANF, ADXN, BMRA, and EVOK Company DescriptionsAddex Therapeutics NASDAQ:ADXN$8.06 -0.68 (-7.73%) As of 08/29/2025 03:57 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.Biomerica NASDAQ:BMRA$3.13 -0.03 (-0.95%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$3.25 +0.12 (+3.83%) As of 08/29/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.Can-Fite BioPharma NYSE:CANF$0.63 -0.03 (-4.84%) Closing price 08/29/2025 03:59 PM EasternExtended Trading$0.64 +0.01 (+2.15%) As of 08/29/2025 06:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.Evoke Pharma NASDAQ:EVOK$5.45 +0.16 (+3.02%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$5.37 -0.08 (-1.47%) As of 08/29/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
